Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia

Strahlentherapie und Onkologie

Volumn 190, Issue 11, 2014, Pages 1080-1081

  Lang, Nina ^a   Sterzing, Florian ^a   Enk, Alexander H ^a   Hassel, Jessica C ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; SULFONAMIDE;

FEMALE; HUMAN; MALE; MELANOMA; SCALP DERMATOSES; SKIN NEOPLASMS; SKULL IRRADIATION;

ANTINEOPLASTIC AGENTS; CRANIAL IRRADIATION; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; SCALP DERMATOSES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84922332700     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0707-0     Document Type: Letter

References (4)

1. Harding JJ, Barker CA, Carvajal RD et al (2014) Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. J Clin Oncol 32:e54–56
2. Boussemart L, Routier E, Mateus C et al (2013) Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 24:1691–1697
3. Schulze B, Meissner M, Wolter M et al (2014) Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Strahlenther Onkol 190:229–232
4. Rompoti N, Schilling B, Livingstone E et al (2013) Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity. J Clin Oncol 31:3844–3845